Peptides DB
Research-centric peptide and protocol reference hub
Study 24 of 26Orforglipron (LY-3502970) literatureAmerican journal of nephrology · Review

Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.

Orforglipron shows promise in reducing certain metabolic parameters, but its effects on kidney health remain uncertain until further trials specifically address renal outcomes.

Read at American journal of nephrologyAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
8
Preclinical
6
Observational
1
Open-label
5
Randomised
6
Reviews · this one

Summary and findings

Orforglipron, an oral non-peptide GLP-1 receptor agonist, was reviewed for its potential in chronic kidney disease (CKD). Phase 3 trials indicated significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers, with stable eGFR. However, these trials were not designed to evaluate renal outcomes.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.

Abstract

The authors’ words, as American journal of nephrology supplied them

Orforglipron, the first oral non-peptide GLP-1 receptor agonist, has a pharmacokinetic and formulation profile that may be theoretically attractive for patients with chronic kidney disease (CKD) including hepatic metabolism with minimal renal excretion and removal of potential barriers associated with current injectable and other oral formulations. We utilized a literature search utilizing PubMed/MEDLINE and ClinicalTrials. gov from their respective inceptions through May 2026 to synthesize a review on orforglipron. Phase 3 trials demonstrated significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers with stable eGFR and no indications of significant renal toxicity. These trials however were not designed or powered to evaluate renal outcomes including eGFR, albuminuria, and kidney failure progression. Additionally, previous trials were noted to have underrepresented or excluded populations of patients with advanced CKD, thus renal effects are inferential barring further clinical investigation, though a current trial examining kidney and cardiovascular outcomes in patients with both atherosclerosis and CKD is underway. Future CKD-specific trials are necessary to determine the safety, efficacy, and potential integration of orforglipron into nephrology treatment algorithms.

Background

This paper addresses the renal implications of orforglipron, the first oral non-peptide GLP-1 receptor agonist. Prior knowledge indicates that GLP-1 receptor agonists can impact metabolic parameters, but their effects on renal outcomes in CKD patients remain unclear. This study is significant as it highlights the need for further investigation into the renal safety and efficacy of orforglipron in CKD populations.

Methods

The study utilized a literature search from PubMed/MEDLINE and ClinicalTrials.gov through May 2026 to synthesize existing data on orforglipron. It reviewed phase 3 trials focusing on metabolic outcomes and renal safety. Specific details on population size, dose, and duration were not provided in the abstract.

Results

Phase 3 trials demonstrated significant reductions in hemoglobin A1c and body weight, with stable eGFR. However, these trials were not designed to evaluate renal outcomes, and specific numeric findings related to renal function were not reported.

Interpretation

While the findings indicate some metabolic benefits of orforglipron, the lack of specific evaluation for renal outcomes limits the conclusions that can be drawn regarding its safety and efficacy in CKD patients. The underrepresentation of advanced CKD populations in trials raises concerns about the generalizability of the results. Therefore, further clinical trials are necessary to establish the role of orforglipron in nephrology.

Key findings

  • Significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers.
  • Stable eGFR reported in phase 3 trials.
  • No indications of significant renal toxicity.
  • Trials were not designed or powered to evaluate renal outcomes including eGFR, albuminuria, and kidney failure progression.
  • Underrepresented or excluded populations of patients with advanced CKD.

Limitations

  • Trials not designed to evaluate renal outcomes.
  • Underrepresented or excluded populations of patients with advanced CKD.
  • No specific numeric findings related to renal function reported.

Elsewhere in the Orforglipron (LY-3502970) corpus

AEfficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.BMC endocrine disorders · 2026 · n=3459 · Percentage body weight change p < 0.00001.reviewAPredicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.Diabetes, obesity & metabolism · 2026 · -48.6% to -59.4% relative reduction in T2D risk score vs placebo (-10.5%; p<0.0001; HR-range 0.43-0.55)HumanBExploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023 · For a representative 50-year-old man with T2D, the PCE estimated a 10-year RRR of 16.8% at the 36 mg dose, while PREVENT projected an RRR of 31.4% at the same dose.reviewCVariant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.International journal of biological macromolecules · 2026 · G168S exhibited the strongest binding (-117.18 kcal/mol)In vitroBEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Annals of internal medicine · 2024 · n=25816 · -12.4% placebo-subtracted weight loss for orforglipron (95% CI, -15.1% to -9.7%)reviewALong-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.The lancet. Diabetes & endocrinology · 2023 · n=401 · 339 participants (85%, 95% CI 80·7-87·8) had at least one treatment-emergent adverse event (TEAE).Human